Antisense properties of 2'-O-dimethylaminooxyethyl (2'-O-DMAOE) oligonucleotides

Blood brain barrier precludes the cerebral arteries to intravenously-injected antisense oligonucleotide

Alternative splicing of the ryanodine receptor subtype 3 (RyR3) produces a short isoform (RyR3S) able to negatively regulate the ryanodine receptor subtype 2 (RyR2), as shown in cultured smooth muscle cells from mice. The RyR2 subtype has a crucial role in the control of vascular reactivity via the fine tuning of Ca(2+) signaling to regulate cerebral vascular tone. In this study, we have shown that the inhibition of RyR3S expression by a specific antisense oligonucleotide (asRyR3S) was able to increase the Ca(2+) signals implicating RyR2 in cerebral arteries ex vivo. Moreover, we tried to inhibit the expression of RyR3S in vivo. The asRyR3S was complexed with JetPEI and injected intravenously coupled with several methods known to induce a blood brain barrier disruption. We tested solutions to induce osmotic choc (mannitol), inflammation (bacteria lipopolysaccharide and pertussis toxin), vasoconstriction or dilatation (sumatriptan, phenylephrine, histamine), CD73 activation (NECA) and lipid instability (Tween80). All tested technics failed to target asRyR3 in the cerebral arteries wall, whereas the molecule was included in hepatocytes or cardiomyocytes. Our results showed that the RyR3 alternative splicing could have a function in cerebral arteries ex vivo; however, the disruption of the blood brain barrier could not induce the internalization of antisense oligonucleotides in the cerebral arteries, in order to prove the function of RYR3 short isoform in vivo.

Designing highly active siRNAs for therapeutic applications

The discovery of RNA interference (RNAi) generated considerable interest in developing short interfering RNAs (siRNAs) for understanding basic biology and as the active agents in a new variety of therapeutics. Early studies showed that selecting an active siRNA was not as straightforward as simply picking a sequence on the target mRNA and synthesizing the siRNA complementary to that sequence. As interest in applying RNAi has increased, the methods for identifying active siRNA sequences have evolved from focusing on the simplicity of synthesis and purification, to identifying preferred target sequences and secondary structures, to predicting the thermodynamic stability of the siRNA. As more specific details of the RNAi mechanism have been defined, these have been incorporated into more complex siRNA selection algorithms, increasing the reliability of selecting active siRNAs against a single target. Ultimately, design of the best siRNA therapeutics will require design of the siRNA itself, in addition to design of the vehicle and other components necessary for it to function in vivo. In this minireview, we summarize the evolution of siRNA selection techniques with a particular focus on one issue of current importance to the field, how best to identify those siRNA sequences likely to have high activity. Approaches to designing active siRNAs through chemical and structural modifications will also be highlighted. As the understanding of how to control the activity and specificity of siRNAs improves, the potential utility of siRNAs as human therapeutics will concomitantly grow.

Relationship between expression of P-glycoprotein and efficacy of chemotherapy in gastric cancer

AIM: To investigate the significance of the expression of P-glycoprotein and the relationship between its expression and the efficacy of chemotherapy in patients with gastric cancer.

METHODS: P-glycoprotein was examined by immunohistochemical staining in 101 specimens of paraffin embedded gastric cancer tissues.

RESULTS: The expression rates of P-glycoprotein in normal gastric mucosa, paracancerous tissues and gastric cancer tissues were 13%, 22% and 43%, respectively (P < 0.05). The expression rates of P-glycoprotein in the highly and moderately differentiated tumors (58% and 80%, respectively) were significantly higher than those in the lowly and poorly differentiated tumors (36% and 25%, respectively) (P < 0.01). The postoperative cumulative survival rate of the patients receiving chemotherapy was significantly higher than that of the patients without chemotherapy in P-glycoprotein-negative patients with gastric cancer (P < 0.01).

CONCLUSION: The expression of P-glycoprotein was correlated with the degree of tumor differentiation and influenced the efficacy of postoperative chemotherapy.